We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
In this webinar, get a comprehensive overview of the UK’s biotech and life sciences presence at BIO 2025. Learn about the UK delegation’s plans, including the UK Pavilion organised by the Department for Business and Trade.
Our response to the Government’s consultation highlights the value of secure health data access for biotechs, the risks of uncontrolled broker use, and more.
BIA has responded to the call for evidence, highlighting the urgent need to close the scale-up funding gap and calling for pension fund reform to keep innovation and economic growth in the UK.
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
BIA has responded to the DBT's consultation on potential UK tariffs in response to US measures, urging to protect life sciences supply chains, innovation, and patient access.
Our response supported stronger HMRC powers to reduce fraud in the R&D tax relief system while protecting legitimate claims that drive innovation and economic growth.
In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.
Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.
Maxion Therapeutics, a biotech company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced a $72 million raise in a Series A financing.
This report is the first step in understanding the specific challenges faced by female CEOs and C-suite in biotechnology in the UK – in order to understand best how we can help to enact change and provide relevant support.
The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker.